Hologic Inc at Raymond James Institutional Investors Conference (Virtual) Transcript
Okay. I think we can get started here. My name is Jayson Bedford, Medical Device Analyst here at Raymond James. Welcome to the afternoon session, at least on the East Coast, to the Raymond James -- 42nd Annual Raymond James Institutional Investor Conference. Very pleased to have with us today Hologic. Representing Hologic, we've got Mike Watts, VP of Investor Relations and Corporate Communications; and Francis Pruell, Director of Investor Relations. So there'll be no presentation. It will be straight fireside.
Just wanted to, before we begin, kind of, at least frame the investment dynamic as we see it at least. You've got a little less than half of your revenue stemming from COVID testing, a little over half currently from non-COVID testing. There's clearly a debate out there on the durability and relative share of the testing market, but pretty much everyone agrees testing will come down over time. We've started to see that in the public data. Like, this is factored into
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
